TRANCE/TNFSF11/RANK L Antibody (IK22-5) - Chimeric - Azide and BSA Free

• Reactivity: Mu
• Applications: Flow, IHC, B/N
• Clone: IK22-5
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: 1 mg/ml

TRANCE/TNFSF11/RANK L Antibody (IK22-5) - Chimeric - Azide and BSA Free Summary

• Description: Novus Biologicals Rabbit TRANCE/TNFSF11/RANK L Antibody (IK22-5) - Chimeric - Azide and BSA Free (NBP2-81123) is a recombinant monoclonal antibody validated for use in IHC and Flow. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Thus antibody was raised by immunising an SD rat with murine TRANCE/TNFSF11/RANK L-transfected baby hamster kidney cells.
• Specificity: This antibody is specific for murine TRANCE/TNFSF11/RANK L.
• Isotype: IgG Kappa
• Clonality: Monoclonal
• Host: Rabbit
• Gene: TNFSF11
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry
  • Immunohistochemistry
  • Neutralization
• Application Notes: This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. This antibody has been used in immunohistochemical analysis of frozen Peyer's patch tissue sections (Kobayashi et al, 2013). It has also been used in flow cytometric analysis of RANKL cell surface expression by Th1 and Th17 cells (Nakae et al, 2007), RANKL-transfected human embryonic kidney cells (Miyahira et al, 2003) and murine T hybridoma 2B4.11 cells (Fionda et al, 2007). Additionally, this RANKL-neutralising antibody has been used to assess the effects of RANKL inhibition on myoepithelial cell proliferation in mammary organoid culture (Haslam et al, 2008). Treatment of collagen-induced arthritis (CIA) mice with this antibody has been shown to reduce bone loss at the site of inflammation (Kamijo et al, 2006), while administration to C57BL/6J mice induced transient tibia and skull bone growth arrest and irreversible blockage of tooth eruption (Lezot et al, 2015).

Packaging, Storage & Formulations

• Storage: Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
• Buffer: PBS
• Preservative: 0.02% Proclin 300
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for TRANCE/TNFSF11/RANK L Antibody (IK22-5) - Chimeric - Azide and BSA Free

• CD254 antigen
• CD254
• ODF
• OPGL
• OPGLOPTB2
• Osteoclast differentiation factor
• Osteoprotegerin ligand
• RANK L
• RANKL
• RANKLreceptor activator of nuclear factor kappa B ligand
• Receptor activator of nuclear factor kappa-B ligand
• sOdf
• TNF-related activation-induced cytokine
• TNFSF11
• TRANCE
• TRANCEODFhRANKL2
• tumor necrosis factor (ligand) superfamily, member 11
• tumor necrosis factor ligand superfamily member 11

Background

TRANCE/OPGL/RANKL/ODF is a recently identified member of tumor necrosis factor family. TRANCE (TNF-related activation-induced cytokine receptor) or RANKL {receptor activator of NF-kB (RANK) ligand} has been implicated in interactions between T cells and dendritic cells (1-2). RANK ligand (RANKL/TRANCE) binds to RANK on dendritic cells, upregulates the expression of anti-apoptotic protein BcL-XL suggesting a role in dendritic cell survival (2). TRANCE/RANKL is also important in T and B-cell maturation (3). As OPGL/ODF (Osteoprotegerin Ligand/Osteoclast differentiation factor), the same protein can both activate mature osteoclasts and mediate osteoclastogenesis (4). OPGL/TRANCE deficient mice show severe osteoporesis and complete absence of osteoclasts as a result of lack of osteogenesis (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: TNFSF11